



Fenwal, Inc.  
Attention: Ms. Jody Stoughtenger  
Fresenius Kabi USA, LLC  
Three Corporate Drive, 2<sup>nd</sup> floor  
Lake Zurich, IL 60047

April 3, 2017

Re: BK170001  
Device Name: Alyx Component Collection System  
Regulation Number: 21 CFR 864.9245  
Regulation Name: Automated Blood Cell Separators  
Regulatory Class: II  
Product Code: GKT  
Dated: March 27, 2017  
Received: March 28, 2017

Dear Ms. Stoughtenger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to a legally marketed predicate device marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely,

Orieji Illoh, MD  
Director  
Division of Blood Components and Devices  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research

Enclosure  
Indications For Use

## Indications for Use

510(k) Number: BK170001

Device Name: Alyx Component Collection System

Indications for Use:

The ALYX Component Collection System is intended for use in blood collection establishments to collect and separate whole blood into its components.

Depending on the ALYX Component Collection system apheresis kit used in the collection of products, the ALYX Component Collection system has been cleared for:

- Concurrent collection of two units of Red Blood Cells (2RBC), Leukocytes Reduced
  - Single Unit Recovery (One Unit of Red Blood Cells, Non-Leukocytes Reduced) permitted
- Concurrent collection of two units of Red Blood Cells (2RBC), Non-Leukocytes Reduced
  - Single Unit Recovery (One Unit of Red Blood Cells, Non-Leukocytes Reduced) permitted
- Concurrent collection of One Unit of Red Blood Cells, Leukocytes Reduced, and Plasma as
  - Fresh Frozen Plasma,
    - Must be prepared and placed in a freezer at -18°C or colder within 8 hours after phlebotomy.
  - Source Plasma
  - Plasma Frozen Within 24 Hours After Phlebotomy (PF24)
    - Must be stored at 1-6°C within 8 hours after phlebotomy and placed in a freezer at -18°C or colder within 24 hours after phlebotomy.
    - Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma.
  - Plasma Frozen Within 24 Hours After Phlebotomy Held At Room Temperature Up To 24 Hours After Phlebotomy (PF24RT24)
    - *Can be stored at room temperature for up to 24 hours after phlebotomy. Product must be placed in a freezer at -18°C or colder within 24 hours after phlebotomy*
    - Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma.
- Collection of Plasma as
  - Fresh Frozen Plasma,
    - Must be prepared and placed in a freezer at -18°C or colder within 8 hours after phlebotomy.
  - Source Plasma
  - Plasma Frozen Within 24 Hours After Phlebotomy (PF24)
    - Must be stored at 1-6°C within 8 hours after phlebotomy and placed in a freezer at -18°C or colder within 24 hours after phlebotomy.
    - Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma.

- Plasma Frozen Within 24 Hours After Phlebotomy Held At Room Temperature Up To 24 Hours After Phlebotomy (PF24RT24)
  - Can be stored at room temperature for up to 24 hours after phlebotomy. Product must be placed in a freezer at -18°C or colder within 24 hours after phlebotomy.
  - Indicated for replacement of non-labile clotting factors. This product is not equivalent to Fresh Frozen Plasma.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CBER, Office of Device Evaluation (ODE)

---

Division Sign-Off, Office of Blood Research and Review